Core Viewpoint - Kanghong Pharmaceutical (002773.SZ) announced that its subsidiary Chengdu Hongji Biotechnology Co., Ltd. received the Clinical Trial Approval Notice from the National Medical Products Administration for the drug KH631, an eye injection for the treatment of diabetic macular edema (DME) [1] Group 1 - The drug KH631 is classified as a Class 1 therapeutic biological product and has received approval to conduct clinical trials for DME [1] - The approval numbers for the drug are CXSL2500874 and CXSL2500875 [1] - KH631 is an innovative gene therapy product developed by Hongji Biotechnology, which has also received approval from the U.S. Food and Drug Administration to conduct clinical trials for neovascular (wet) age-related macular degeneration (nAMD) [1] Group 2 - The product utilizes a proprietary adeno-associated virus (AAV) delivery system, which features specificity for tissues, low immunogenicity, controllable expression, and high infection efficiency [1] - Preclinical disease models have demonstrated sustained efficacy for KH631 [1]

Core Viewpoint - Kanghong Pharmaceutical's subsidiary, Hongji Biotech, has received approval from the National Medical Products Administration to conduct clinical trials for KH631 eye injection, aimed at treating diabetic macular edema (DME) [1] Group 1: Product Development - KH631 eye injection is an innovative gene therapy product independently developed by Hongji Biotech, classified as a Class 1 therapeutic biological product [1] - The product utilizes a self-owned intellectual property adeno-associated virus (AAV) delivery system, which features specificity for tissues, low immunogenicity, controllable expression, and high infection efficiency [1] - Preclinical disease models have demonstrated sustained efficacy of KH631 [1]

（来源：光明日报） 转自：光明日报 本报北京1月3日电（记者晋浩天）如同导演一声令下，舞台演员便能瞬间变换队形、组合或散开，科学 家如今也有望如此精准地指挥生命体内的蛋白质"集体行动"。西湖大学生命科学学院曹龙兴实验室，与 西湖大学医学院解明岐实验室合作实现前沿突破：研究团队成功从头设计出一套能被口服小分子药物精 准调控的蛋白质多聚化系统，如同掌握了让蛋白质"组队"与"解散"的"遥控开关"，向"编程生命"的愿景 迈出了关键一步。相关成果日前在线发表于国际学术期刊《科学》。 此后，团队进一步拆解与改造系统，先后成功创建了"异源二聚体工具"AMA10和更复杂的"异源三 聚体系统"。这意味着，研究者如今可以像指挥不同乐手合奏一样，精确控制两个或三个不同蛋白质仅 在需要时"组队"协作。 "为确保这套系统在活体中同样有效，研究进入了关键的细胞与动物验证阶段。实验结果令人振 奋：在细胞内，新系统成功实现了由药物精准调控的基因开关激活、特定蛋白质的定位引导以及蛋白质 相变调控；在小鼠实验中，静脉注射携带该系统和报告基因的质粒后，仅通过口服金刚烷胺，便成功激 活了小鼠肝脏内的报告基因表达。"解明岐表示："这预示了未来基因治疗 ...

Core Insights - The pharmaceutical industry is experiencing significant performance divergence among major multinational companies in 2025, with some achieving remarkable growth while others face substantial declines [1][4][6]. Financial Performance - Novo Nordisk reported Q3 2025 revenues of 74.976 billion Danish Krone (approximately $11.276 billion), a year-on-year increase of 11%, with total revenues for the first three quarters reaching 229.92 billion Danish Krone (approximately $34.58 billion), up 15% [1]. - Merck's pharmaceutical business revenue for the first three quarters of 2025 was $43.299 billion, with a 68% year-on-year decline in revenue from China, dropping to $1.452 billion [2]. - Eli Lilly achieved a Q3 2025 revenue of $17.6 billion, a 54% increase from $11.439 billion in the same period last year, with total revenues for the first three quarters reaching $45.887 billion, up 46% [3]. - Pfizer's Q3 2025 total revenue was $16.654 billion, a 6% decrease from $17.702 billion year-on-year, with a 55% drop in revenue from its COVID-19 oral drug Paxlovid [4]. Strategic Adjustments - Major pharmaceutical companies are actively seeking solutions to address strategic challenges, including layoffs and business divestitures, with 190 layoffs reported in the biopharmaceutical sector in the first three quarters of 2025 [2][9]. - Companies like Merck and Novo Nordisk are implementing significant cost-cutting measures, with Merck aiming to save $3 billion by 2027 and Novo Nordisk targeting an annual cost saving of 8 billion Danish Krone [9]. - The trend of divesting mature assets is becoming common, with investment firms stepping in as buyers, indicating a shift in the operational landscape of the pharmaceutical industry in China [7][8]. Market Dynamics - The Chinese market is no longer a guaranteed profit zone for multinational pharmaceutical companies, with significant performance disparities emerging among leading firms [5][12]. - The ongoing "patent cliff" is a critical concern, with many companies facing over 20% revenue exposure to patent expirations in the next three years, impacting their financial stability [4][5]. - The competition in the pharmaceutical sector is intensifying, necessitating companies to adapt quickly to local market policies and innovate their product pipelines to maintain growth [6][12]. Future Outlook - The future of multinational pharmaceutical companies will heavily rely on their innovation capabilities, local market strategies, and management of patent expirations [12][15]. - Companies that successfully transition to innovation-driven models and establish strong positions in emerging therapeutic areas are likely to thrive, while those unable to adapt may face ongoing growth pressures [12][15]. - The restructuring of global pharmaceutical strategies is expected to accelerate, focusing on both downsizing and investing in innovative fields, such as gene and cell therapies [9][10].

Core Insights - Frontera Therapeutics has submitted its listing application to the Hong Kong Stock Exchange, focusing on innovative gene therapies for patients globally [1] - The company has developed a pipeline of eight recombinant adeno-associated virus (rAAV) gene therapy candidates, with FT-002 and FT-003 being the core products [1][2] Company Overview - Founded in 2019, Frontera Therapeutics specializes in developing rAAV gene therapies, particularly for ophthalmic and cardiovascular diseases [2] - The company has advanced three candidates to Phase II clinical trials, including FT-002 for X-linked retinitis pigmentosa (XLRP) and FT-003 for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) [2] Financial Performance - As of the third quarters of 2023, 2024, and 2025, the company reported net losses of $35.86 million, $26.464 million, and $13.311 million, respectively [4] - Research and development expenses for the same periods were $27.585 million, $20.576 million, and $10.969 million, respectively [4] Use of Proceeds - The funds raised from the listing are intended for continued clinical development of core products FT-002 and FT-003, commercialization preparations in China, and investments in production capabilities [3] Regulatory Status - As of December 16, 2025, Frontera Therapeutics has not obtained any marketing approvals for its candidates and has not generated any revenue from product sales [4] - The company plans to adopt a flexible commercialization strategy in China, combining internal sales teams with professional partners [4]

Summary of Key Points from Biotechnology Equity Research Conference Call Industry Overview - The report focuses on the biotechnology sector, specifically highlighting companies with significant potential for growth and upcoming catalysts in 2026. Key Companies and Their Outlook 1. **Dianthus Therapeutics, Inc. (DNTH)** - Market Cap: $1.82 billion - Price Target: $66 - Key catalysts include: - CIDP Phase III interim analysis in Q2 2026 - Initiation of gMG Phase III study in mid-2026 - Phase II MMN topline data in 2H26 - Potential for significant upside based on peak revenue estimates of ~$2 billion across neuromuscular diseases [19][20][24] 2. **Taysha Gene Therapies, Inc. (TSHA)** - Market Cap: $1.50 billion - Price Target: $11 - Focus on pivotal study for TSHA-102 in Rett syndrome with potential for a 6-month interim readout by YE26/1Q27 [26][27] 3. **Tyra Biosciences (TYRA)** - Market Cap: $1.36 billion - Price Target: $32 - Major catalysts include: - Phase III data for achondroplasia in early 2026 - Initial data for IR-NMIBC in 1H26 - Potential to disrupt the market with oral FGFR3 inhibitors [31][35] 4. **Tango Therapeutics, Inc. (TNGX)** - Market Cap: $1.15 billion - Price Target: $14 - Expected to show de-risking data for vopimetostat in combination with RVMD's RAS inhibitors in 2026 [37][40] 5. **ORIC Pharmaceuticals (ORIC)** - Market Cap: $783 million - Price Target: $23 - Key catalysts include dose-optimization data for prostate cancer and validating data from PFE's MEVPRO-1 trial [42][48] 6. **Solid Biosciences (SLDB)** - Market Cap: $463 million - Price Target: $15 - Focus on DMD program with key regulatory feedback expected in 1H26 [49][53] Major Catalysts and Events - **Upcoming Catalysts:** - RARE and MREO Phase III ORBIT final analysis expected in Dec'25/Jan'26 with potential stock movements of +100%/-30% [2] - ALNY, CRSP, and others expected to provide revenue guidance and business plans early in 2026 [1] - Regulatory events including FDA's Rare Disease Day on 2/23/26 [12] - **Drug Launches:** - Expected launches in 2026 include drugs from ALNY, ARWR, KALV, and others targeting various conditions [3] Financial Updates - **Price Target Changes:** - ARWR raised from $67 to $90 - KOD raised from $24 to $39 [6][10] Market Dynamics - **Pricing Stability:** - 2026 net pricing expected to remain stable with current Medicare contracts influencing high gross-to-net (GTN) guidance [12] - **Strategic Interest:** - Potential for M&A activity as companies like ORIC attract interest due to their prostate cancer programs [43] Conclusion - The biotechnology sector is poised for significant developments in 2026, with multiple companies presenting strong investment opportunities based on upcoming catalysts, drug launches, and strategic positioning in the market.

Core Viewpoint - Frontera Therapeutics has submitted its application for listing on the Hong Kong Stock Exchange, aiming to become the first publicly traded company focused on AAV gene therapy [1] Company Overview - Founded in 2019, Frontera Therapeutics specializes in the development of innovative recombinant adeno-associated virus (rAAV) gene therapies, with a product pipeline that includes eight self-developed rAAV gene therapy candidates [1][2] - The company is currently in the clinical development stage and has no commercialized products yet [3] Product Pipeline - The core product FT-002 is being researched for the treatment of X-linked retinitis pigmentosa (XLRP), while FT-003 is being studied for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) [2] - Both FT-002 and FT-003 have completed Phase II clinical recruitment in China, with FT-003 expected to begin Phase III trials for nAMD by Q3 2026 [2] Financial Performance - The company reported losses of $35.9 million for the year ending December 31, 2023, and $26.5 million for the year ending December 31, 2024, with a loss of $13.3 million recorded in the first nine months of 2025 [3] - The funds raised from the IPO are intended for the continued clinical development of its core products and early pipeline projects [3] Market Context - Since 2015, the U.S. has approved 16 gene therapy products, with the first gene therapy in China expected to be approved by April 1, 2025 [3] - The high costs associated with gene therapies, such as Luxturna priced at approximately $850,000 per treatment, pose challenges for commercialization [3] Shareholder Structure - The largest single shareholder is Hongyuan, holding 27.7% of the shares, while the company is managed independently of its founding shareholders [5] - The board consists of nine directors, with CEO and co-founder Li Xinyan having over 20 years of experience in innovative drug development [5]

Company Overview - Frontera Therapeutics has submitted a listing application to the Hong Kong Stock Exchange, with UBS and Haitong International as joint sponsors [1] - The company's core business focuses on the development of innovative recombinant adeno-associated virus (rAAV) gene therapies, particularly targeting ophthalmic and cardiovascular diseases [1] - Frontera Therapeutics' product pipeline is considered to have best-in-class potential globally [1] Product Pipeline - As of December 16, 2025, Frontera Therapeutics' product pipeline includes eight self-developed rAAV gene therapy candidates [1] - The two core products are FT-002 for treating X-linked retinitis pigmentosa (XLRP) and FT-003 for treating neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) [1] Competitive Advantages - The company possesses the AAVANCETM Bac/Sf9 production platform, which enables safe, scalable, and cost-effective high-quality production [1] - Frontera Therapeutics also has the EXACTETM proprietary rAAV gene therapy R&D platform, supporting the development of innovative products protected by global intellectual property rights [1] Regulatory Approvals - Frontera Therapeutics has received a total of 12 IND approvals from the National Medical Products Administration and the FDA, making it the company with the most IND approvals for rAAV gene therapy development in China [1] - The company has successfully advanced three candidate drugs into Phase II clinical trials [1] Industry Growth - The global gene therapy market is projected to grow from $2.8 billion in 2024 to $32 billion by 2035 [2] - The Chinese gene therapy market is also expected to experience rapid growth, reaching a market size of RMB 11.6 billion by 2035 [2]

Core Viewpoint - Frontera Therapeutics has submitted an application for listing on the Hong Kong Stock Exchange, indicating its intention to raise capital for further development in the gene therapy sector [1] Company Overview - Frontera Therapeutics is a clinical-stage gene therapy company focused on developing innovative therapies [1] - The company was established in 2019 and has been dedicated to the development of recombinant adeno-associated virus (rAAV) gene therapies [1] - It aims to provide safe, effective, and affordable gene therapy solutions for patients worldwide [1] Product Pipeline - Frontera Therapeutics has developed a differentiated pipeline with clinical advancements, particularly targeting ophthalmic and cardiovascular diseases [1] - The company’s pipeline is positioned to have global best-in-class potential in its therapeutic areas [1] Financial and Market Position - UBS Securities Hong Kong Limited and Haitong International Capital Limited are acting as joint sponsors for the listing application [1]

Core Viewpoint - Frontera Therapeutics has submitted a listing application to the Hong Kong Stock Exchange, aiming to develop innovative gene therapies with a focus on affordability and effectiveness for patients worldwide [1]. Company Overview - Frontera Therapeutics is a clinical-stage gene therapy company founded in 2019, specializing in the development of innovative therapies [1]. - The company has a global business presence and is dedicated to creating effective and affordable gene therapy solutions for patients around the world [1]. - Frontera Therapeutics has developed a leading pipeline of innovative recombinant adeno-associated virus (itAAV) gene therapies, particularly targeting ophthalmic and cardiovascular diseases [1]. Financial and Advisory Information - UBS Securities Hong Kong Limited and Haitong International Capital Limited are acting as joint sponsors for Frontera Therapeutics' listing application [1].